Vanguard Group Inc. Has $92.48 Million Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Vanguard Group Inc. lifted its stake in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 11.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,662,671 shares of the company's stock after acquiring an additional 277,906 shares during the quarter. Vanguard Group Inc. owned about 4.51% of Ventyx Biosciences worth $92,475,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in VTYX. BlackRock Inc. boosted its stake in shares of Ventyx Biosciences by 57.5% during the 2nd quarter. BlackRock Inc. now owns 3,226,572 shares of the company's stock worth $105,832,000 after acquiring an additional 1,177,971 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Ventyx Biosciences by 163.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,805,574 shares of the company's stock valued at $59,205,000 after purchasing an additional 1,120,232 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in Ventyx Biosciences by 962.7% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 987,970 shares of the company's stock valued at $34,312,000 after purchasing an additional 895,000 shares during the period. FMR LLC boosted its stake in Ventyx Biosciences by 92.9% during the 2nd quarter. FMR LLC now owns 1,575,942 shares of the company's stock valued at $19,274,000 after purchasing an additional 758,903 shares during the period. Finally, Holocene Advisors LP boosted its stake in Ventyx Biosciences by 48.3% during the 2nd quarter. Holocene Advisors LP now owns 1,537,084 shares of the company's stock valued at $50,416,000 after purchasing an additional 500,571 shares during the period. Institutional investors own 97.88% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on VTYX. Wells Fargo & Company upgraded Ventyx Biosciences from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $7.00 to $16.00 in a research note on Tuesday, March 12th. Oppenheimer upgraded Ventyx Biosciences from a "market perform" rating to an "outperform" rating and set a $12.00 target price for the company in a research note on Tuesday, March 12th. Canaccord Genuity Group decreased their target price on Ventyx Biosciences from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Wednesday, March 13th. Finally, Lifesci Capital upgraded Ventyx Biosciences from a "market perform" rating to an "outperform" rating in a research note on Wednesday, February 28th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Ventyx Biosciences has a consensus rating of "Moderate Buy" and an average price target of $21.75.

Ventyx Biosciences Price Performance

Shares of VTYX traded down $0.06 during mid-day trading on Friday, reaching $4.84. The company had a trading volume of 828,784 shares, compared to its average volume of 2,061,159. Ventyx Biosciences, Inc. has a twelve month low of $1.87 and a twelve month high of $40.58. The company's 50-day moving average is $5.45 and its 200-day moving average is $8.38. The company has a market capitalization of $286.77 million, a P/E ratio of -1.47 and a beta of 0.27.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.79) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.08. During the same period last year, the firm earned ($0.62) EPS. As a group, equities analysts expect that Ventyx Biosciences, Inc. will post -2.55 EPS for the current fiscal year.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.